Teva and medincell announce fda acceptance of supplemental new drug application for uzedy(r) (risperidone) extended-release injectable suspension as a treatment for patients with bipolar i disorder

Parsippany, n.j. and tel aviv, israel and paris, feb. 25, 2025 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and medincell (euronext: medcl) announced today that the supplemental new drug application (snda) for uzedy extended-release injectable suspension for the maintenance treatment of bp-i in adults has been accepted for filing by the u.s. food and drug administration (fda).
TEVA Ratings Summary
TEVA Quant Ranking